Reduced costs with bisoprolol treatment for heart failure - An economic analysis of the second Cardiac Insufficiency Bisoprolol Study (CIBIS-II)

Background Beta-blockers, used as an adjunctive to diuretics, digoxin and angiotensin converting enzyme inhibitors, improve survival in chronic heart failure. We report a prospectively planned economic analysis of the cost of adjunctive beta-blocker therapy in the second Cardiac Insufficiency BIsoprolol Study (CIBIS II). Methods Resource utilization data (drug therapy, number of hospital admissions, length of hospital stay, ward type) were collected prospectively in all patients in CIBIS . These data were used to determine the additional direct costs incurred, and savings made, with bisoprolol therapy. As well as the cost of the drug, additional costs related to bisoprolol therapy were added to cover the supervision of treatment initiation and titration (four outpatient clinic/office visits). Per them (hospital bed day) costings were carried out for France, Germany and the U.K. Diagnosis related group costings were performed for France and the U.K. Our analyses took the perspective of a third party payer in France and Germany and the National Health Service in the U.K. Results Overall, fewer patients were hospitalized in the bisoprolol group, there were fewer hospital admissions perpatient hospitalized, fewer hospital admissions overall, fewer days spent in hospital and fewer days spent in the most expensive type of ward. As a consequence the cost of care in the bisoprolol group was 5-10% less in all three countries, in the per them analysis, even taking into account the cost of bisoprolol and the extra initiation/up-titration visits. The cost per patient treated in the placebo and bisoprolol groups was FF35 009 vs FF31 762 in France, DM11 563 vs DM10 784 in Germany and pound 4987 vs pound 4722 in the U.K. The diagnosis related group analysis gave similar results. Interpretation Not only did bisoprolol increase survival and reduce hospital admissions in CIBIS II, it also cut the cost of care in so doing. This `win-win' situation of positive health benefits associated with cost savings is Favourable from the point of view of both the patient and health care systems. These findings add further support for the use of beta-blockers in chronic heart failure

Quels outils pour mieux maîtriser la végétation forestière concurrente ?

Le renouvellement ou la création de peuplements forestiers peut se trouver bloqué ou dominé par une végétation herbacée, semi-ligneuse ou ligneuse qui exerce une forte compétition. Cette végétation peut être maîtrisée par des techniques plus ou moins efficaces. Il est utile d'expliquer le bon usage, l'efficacité et les limites des outils de lutte contre la végétation indésirable en phase de régénération de la forêt

Facteurs limitants de la croissance initiale d'une plantation de Merisier (Prunus avium L.) sur rendzine brunifiée

International audienc

Facteurs limitants de la croissance initiale d'une plantation de Merisier (Prunus avium L.) sur rendzine brunifiée

International audienc

Efficacité d'un paillage de papier journal sur la croissance initiale du merisier (Prunus avium L.)

International audienc

Efficacité d'un paillage de papier journal sur la croissance initiale du merisier (Prunus avium L.)

International audienc